| abstract |
In some aspects, the invention relates to treatments for peptide aggregation associated with disease states such as neurodegenerative disease, particularly physiology associated with Alzheimer's Disease, and non-neurodegenerative disease aggregation. Other aspects of the invention provide a variety of novel assays for screening candidate drugs. Yet other aspects of the present invention provide a series of compositions useful for treatment of peptide aggregation associated with disease states such as neurodegenerative disease, as determined from these assays. These compositions can be packaged in kits. Other aspects of the invention relate to the use of these compositions for the treatment and/or prevention of patients susceptible to or exhibiting symptoms characteristic of fibril formation or aberrant protein aggregation. |